Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Claudia A.M Stege,Kazem Nasserinejad,Mark-David Levin,Saskia K Klein,Esther De Waal,Corien Eeltink,Charlotte L.B.M Korst,Paula F Ypma,Amanda C Dijk,Matthijs Westerman,Wendy Deenik,Bea Tanis,Monique C Minnema,Henk M.W Verheul,Birgit I Lissenberg-Witte,Niels Wcj Van De Donk,Pieter Sonneveld,Sonja Zweegman

doi:10.1182/blood-2018-99-116920

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Claudia A.M Stege, Kazem Nasserinejad + Show 16 more

Open Access

https://doi.org/10.1182/blood-2018-99-116920

Copy DOI

Journal: Blood	Publication Date: Nov 29, 2018
Citations: 10

Affiliation: Albert Schweitzer Ziekenhuis, Medisch Centrum Leeuwarden, Noordwest Ziekenhuisgroep, Rijnstate Hospital, Amsterdam University Medical Centers, Erasmus MC Cancer Institute, Vrije Universiteit Amsterdam, Tergooi, Groene Hart Ziekenhuis, Haga Hospital, Cancer Center Amsterdam, Meander Medisch Centrum, Utrecht University, University Medical Center Utrecht, Amsterdam UMC Location VUmc

#Low Muscle Mass #Unfit Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Full Text